Synapse - James Harding

Results (250)

Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma

Journal Article

Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
Liver Cancer (2025)

Fulltext@MSK | Save

Adjuvant cytotoxic chemotherapy may not be associated with a survival advantage for resected intrahepatic cholangiocarcinoma

Journal Article

Sharib, J.; Rhodin, K. E.; Liu, A.; McIntyre, S.; Bartholomew, A.; Masoud, S.; DeLaura, I.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; more...
Annals of Surgical Oncology (2025)

Fulltext@MSK | Save

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: Clinical insights and genomic features from a large contemporary cohort

Journal Article

Keane, F.; O’Connor, C.; Moss, D.; Chou, J. F.; Perry, M. A.; Crowley, F.; Saxena, P.; Chan, A.; Schoenfeld, J. D.; Singhal, A.; more...
JNCI: Journal of the National Cancer Institute (2025)

Fulltext@MSK | Save

ASO Visual Abstract: Adjuvant cytotoxic chemotherapy may not be associated with a survival advantage for resected intrahepatic cholangiocarcinoma

Miscellaneous

Sharib, J.; Rhodin, K. E.; Liu, A.; McIntyre, S.; Bartholomew, A.; Masoud, S.; DeLaura, I.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; more...
Annals of Surgical Oncology (2025)

Fulltext@MSK | Save

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy

Journal Article

Cowzer, D.; Soares, K.; Walch, H.; Gönen, M.; Boucher, T. M.; Do, R. K. G.; Harding, J. J.; Varghese, A. M.; Reidy-Lagunes, D.; Saltz, L.; more...
JNCI: Journal of the National Cancer Institute (2025)

Fulltext@MSK | Save

HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)

Meeting Abstract

Harding, J. J.; Macarulla, T.; Pant, S.; Wu, X.; Garfin, P. M.; Okusaka, T.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies

Meeting Abstract

Thummalapalli, R.; Darmofal, M.; Seier, K.; Khalil, D. N.; Walch, H. S.; Shia, J.; Park, W.; El Dika, I. H.; Chatila, W. K.; Schultz, N.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Obesity and biliary tract cancers: Changing epidemiology

Meeting Abstract

Al Mahmasani, L.; Chou, J. F.; Capanu, M.; Srivastava, A.; Sigel, C. S.; Alsuwailem, R.; Berger, M. F.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository